Leukine

(sargramostim)

ApprovedProtein / enzyme

Sargramostim is used to help boost white blood cell production in cancer patients undergoing chemotherapy or bone marrow transplants, helping their immune system recover and fight infections.[2] Leukine is currently approved and in use across 80 indications[4].[1]

Leukine is one of 1498 biologic programs targeting HIV infection. It is currently in Approved.

Indications

306

Total Trials

Active Trials

1,497

Competitors

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionActive, not recruiting

Iris MelanomaCompleted

NeutropeniaActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

Primary Systemic AmyloidosisActive, not recruiting

Cytomegalovirus RetinitisActive, not recruiting

Aplastic AnemiaActive, not recruiting

Respiratory FailureActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerActive, not recruiting

HIV InfectionPhase 3

Active, not recruiting

Iris MelanomaPhase 3

Completed

NeutropeniaPhase 1

Active, not recruiting

Prostate AdenocarcinomaPhase 1

Active, not recruiting

Primary Systemic AmyloidosisPhase 2

Active, not recruiting

Cytomegalovirus RetinitisPhase 3

Active, not recruiting

Aplastic AnemiaPreclinical

Active, not recruiting

Respiratory FailureApproved

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Lung CancerPhase 1

Active, not recruiting

Showing 10 of 80 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Leukine

Sanofi

Approved

19 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

Zolymbus

AbbVie

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

Acupan

YYonsei University

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Study completion

NCT04237623

Phase 2Active, not recruiting

Neuroblastoma

NCT03786783

Q3 2027

Phase 2Active, not recruiting

Neuroblastoma

NCT04385277

Phase 2Not yet recruiting

Lung Cancer

NCT07169617

Q4 2027

Phase 1/2Recruiting

Temozolomide

NCT04211675

Q3 2028

Phase 2Active, not recruiting

Breast Cancer

NCT05455658

Clinical

Trials by Indication[1]

Lymphoma18 trials

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027937

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Unknown status·FFavrille·Phase 2·NCT00258336·56 enrolled

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Withdrawn·MMedstar Health Research Institute·Phase 2·NCT00006669

Show 15 more trials

GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Unknown status·FFrench Innovative Leukemia Organisation·Phase 2·NCT00893477·60 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003397·25 enrolled

Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002697

Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00411086·60 enrolled

Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00308087·75 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00389818·43 enrolled

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

Completed·GGenitope Corporation·Phase 2·NCT00071955

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00621036

Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma

Terminated·FFavrille·Phase 2·NCT00104819·238 enrolled

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00073931·25 enrolled

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00521014·14 enrolled

GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma

Unknown status·FFrench Innovative Leukemia Organisation·Phase 2·NCT00896519·30 enrolled

Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00005601·58 enrolled

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000689·18 enrolled

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00004198

Melanoma17 trials

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00005610·28 enrolled

Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery

Completed·—·Phase 2·NCT00014092

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT00017121·40 enrolled

Show 14 more trials

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Completed·UUltimovacs ASA·Phase 2·NCT04382664·156 enrolled

Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

Completed·JJohn P. Fruehauf·Phase 2·NCT00256282·52 enrolled

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 2·NCT00089193

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Completed·NNational Cancer Institute (NCI)·N/A·NCT00006243·30 enrolled

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Suspended·UUniversity of Virginia·Phase 2·NCT00278122·42 enrolled

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT00003897·18 enrolled

Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma

Completed·MMayo Clinic·Phase 1·NCT00568763·11 enrolled

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 1·NCT00118313

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated·UUniversity of Southern California·Phase 2·NCT00006113·25 enrolled

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003362

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00089063·40 enrolled

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00031733·60 enrolled

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 3·NCT01826864

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00085579

Neuroblastoma14 trials

Combination Chemotherapy in Treating Children With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00003093·573 enrolled

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089258·74 enrolled

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005576·6 enrolled

Show 11 more trials

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01767194·73 enrolled

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00040872

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT04385277·41 enrolled

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00450307·32 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00017368·42 enrolled

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03786783·42 enrolled

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00026312·1,449 enrolled

Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002560·40 enrolled

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06528496·45 enrolled

High-Risk Neuroblastoma Chemotherapy Without G-CSF

Completed·—·N/A·NCT02786719·13 enrolled

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT03794349·94 enrolled

Breast Cancer9 trials

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

Completed·UUniversity of Washington·Phase 2·NCT00343109·38 enrolled

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT01355393·50 enrolled

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Unknown status·—·Phase 2·NCT04197687·480 enrolled

Show 6 more trials

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT00791037·23 enrolled

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Active, not recruiting·UUniversity of Washington·Phase 2·NCT05455658·33 enrolled

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00048893·37 enrolled

Biological Therapy in Treating Women With Metastatic Breast Cancer

Unknown status·SSt. Luke's Medical Center·Phase 1/2·NCT00002780·60 enrolled

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

Completed·UUniversity of Washington·Phase 1·NCT02780401·32 enrolled

Biological Therapy in Treating Women With Stage IV Breast Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00027807·6 enrolled

Multiple Myeloma8 trials

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

Unknown status·MMedical College of Wisconsin·Phase 2·NCT00003163·10 enrolled

Vaccine Therapy in Treating Patients With Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019097

Show 5 more trials

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Completed·UUniversity of Tennessee·Phase 2·NCT00003007

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Completed·MMayo Clinic·Phase 1·NCT00477815·30 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00014508

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT02334865·18 enrolled

Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma

Completed·TThe Cleveland Clinic·Phase 2·NCT00003490·30 enrolled

79 more indications

Prostate Cancer8 trials

Vaccine and Antibody Treatment of Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00113984·30 enrolled

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00108732·50 enrolled

The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

Completed·UUniversity of Colorado, Denver·Phase 1·NCT02250014·19 enrolled

Show 5 more trials

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00450619·44 enrolled

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00450463·64 enrolled

GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer

Completed·TThe Cleveland Clinic·Phase 2·NCT00400517·28 enrolled

GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00305669·24 enrolled

Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

Completed·—·Phase 1/2·NCT00939510·32 enrolled

Chronic Lymphocytic Leukemia6 trials

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00546377·50 enrolled

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Terminated·—·Phase 1·NCT00014560·3 enrolled

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·MMayo Clinic·Phase 2·NCT00669318·41 enrolled

Show 3 more trials

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00323557·39 enrolled

Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00265915

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

Completed·MMayo Clinic·Phase 2·NCT00562328·33 enrolled

Chronic Myelogenous Leukemia6 trials

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002598·30 enrolled

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00050531·94 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Show 3 more trials

Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment

Completed·WWake Forest University Health Sciences·Phase 2·NCT00072579

Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00003561·48 enrolled

Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00002778·40 enrolled

Acute Myeloid Leukemia5 trials

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00004217·55 enrolled

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00066794·69 enrolled

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00046930·449 enrolled

Show 2 more trials

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00630565·12 enrolled

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00023777·71 enrolled

Crohn's Disease4 trials

Open-label Trial of Leukine in Active Crohn's Disease

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00206700·378 enrolled

Study of Sargramostim in Moderately to Severely Active Crohn's Disease

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00329537·11 enrolled

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00206713·264 enrolled

Show 1 more trial

Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease

Completed· Sanofi logo

Sanofi·Phase 2·NCT00206596·127 enrolled

Advanced Cancer4 trials

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Completed·SSt. Vincent Medical Center - Los Angeles·Phase 2·NCT00002475·40 enrolled

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00088413·51 enrolled

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

Completed·YYale University·Phase 1/2·NCT00002950·25 enrolled

Show 1 more trial

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Unknown status·TThe Cleveland Clinic·Phase 1·NCT00004036·30 enrolled

COVID-193 trials

Using GM-CSF as a Host Directed Therapeutic Against COVID-19

Completed·SSingapore General Hospital·Phase 2·NCT04400929·2 enrolled

Study of Sargramostim in Patients With COVID-19

Completed·PPartner Therapeutics, Inc.·Phase 2·NCT04411680·123 enrolled

Sargramostim Use in COVID-19 to Recover Patient Health

Completed·PPartner Therapeutics, Inc.·Phase 2·NCT04707664·600 enrolled

Non-Small Cell Lung Cancer3 trials

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Completed·UUniversity of Washington·Phase 1·NCT00003002·60 enrolled

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00398138·22 enrolled

Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00005630

Colorectal Cancer3 trials

Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer

Completed·SSt. Luke's Medical Center·Phase 1/2·NCT00030342·60 enrolled

Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer

Unknown status·SSt. Luke's Medical Center·Phase 1·NCT00016042

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

Completed·MMichael Morse, MD·Phase 2·NCT00103142·74 enrolled

Leukemia3 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Completed·UUniversity of Nebraska·Phase 2·NCT00002638·30 enrolled

Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia

Completed·—·Phase 1·NCT00003003·29 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002766·170 enrolled

Rhabdomyosarcoma3 trials

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT00003958·702 enrolled

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025363·150 enrolled

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT00002995·483 enrolled

Bone Marrow Transplantation3 trials

Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00003961

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002552·40 enrolled

Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00011934

Effectiveness2 trials

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000850·108 enrolled

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000896·24 enrolled

Chemotherapy2 trials

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00673179·7 enrolled

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00012376·35 enrolled

Malignant Glioma2 trials

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01250470·9 enrolled

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008008·40 enrolled

Acute Lymphoblastic Leukemia2 trials

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002514·1,929 enrolled

Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00053131

Stem Cell Transplantation2 trials

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002599·750 enrolled

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

Completed·CCancer Treatment Centers of America·Phase 2·NCT00003408·40 enrolled

Kidney Cancer2 trials

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Unknown status·HHope Cancer Institute, Inc.·Phase 2·NCT00003181·35 enrolled

Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006483·27 enrolled

Patients With Solid Tumors2 trials

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

Withdrawn·PPartner Therapeutics, Inc.·Phase 2·NCT05284214

HER2-Peptide Vaccination of Patients With Solid Tumors

Completed·TTechnical University of Munich·Phase 1·NCT02276300·2 enrolled

Glioblastoma Multiforme2 trials

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·JJohn Sampson·Phase 2·NCT00643097·40 enrolled

Biological Therapy in Treating Patients With Glioblastoma Multiforme

Completed·TThe Cleveland Clinic·Phase 2·NCT00003185·40 enrolled

Myelodysplastic Syndrome2 trials

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00462605·24 enrolled

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00425477·26 enrolled

Glioblastoma2 trials

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active, not recruiting·RRoswell Park Cancer Institute·Phase 2·NCT02455557·66 enrolled

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Completed·DDavid Peereboom·Phase 2·NCT04013672·41 enrolled

Dendritic Cell2 trials

Sargramostim for Myeloid Dendritic Cell Deficiency

Terminated·UUniversity of Florida·Phase 2·NCT03063242·4 enrolled

Sargramostim for Myeloid Dendritic Cell Deficiency

Completed·JJohns Hopkins University·Phase 1·NCT01871467·2 enrolled

Moderate to Severe Crohn's Disease2 trials

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Completed· Sanofi logo

Sanofi·Phase 3·NCT00206674·286 enrolled

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00295165·33 enrolled

Metastatic Melanoma2 trials

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00071981·175 enrolled

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00006385

Hematologic Cancer2 trials

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·SScripps Health·Phase 2·NCT00003269·20 enrolled

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00304018·5 enrolled

Ovarian Cancer2 trials

p53 Vaccine for Ovarian Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00001827·21 enrolled

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Completed·UUniversity of Washington·Phase 1·NCT00436254·66 enrolled

Myeloid Neoplasm1 trial

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Completed·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT00665002·16 enrolled

Biological Therapy1 trial

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019084

Allogeneic Hematopoietic Cell Transplant1 trial

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00053989·41 enrolled

Primary Peritoneal Cancer1 trial

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

Completed·UUniversity of Virginia·Phase 1·NCT00091273·9 enrolled

Germ Cell Tumor1 trial

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00002594·31 enrolled

Mantle Cell Lymphoma1 trial

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006747·4 enrolled

Completed·SSirius Medicine·Phase 1/2·NCT00091052

Metastatic Cancer1 trial

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00217373·33 enrolled

Brain Tumor1 trial

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Completed·—·Phase 1·NCT00069940

Invasive Fungal Infection1 trial

Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection

Completed·MMedical Research Council·Phase 3·NCT00003315·200 enrolled

Neuroendocrine Carcinoma1 trial

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06202066·60 enrolled

Metastatic Prostate Cancer1 trial

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00064129·42 enrolled

Oligodendroglioma1 trial

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004024·60 enrolled

Soft Tissue Sarcoma1 trial

Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery

Completed·MMayo Clinic·Phase 2·NCT00652860·39 enrolled

Stage III1 trial

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

Completed·UUniversity of Washington·Phase 1·NCT00005023

Immune1 trial

Inhaled GM-CSF Therapy of Autoimmune PAP

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT00901511·18 enrolled

Interleukin1 trial

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

Completed·GGeorgetown University·Phase 2·NCT00003125·24 enrolled

HIV infection1 trial

A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility

Completed· Novartis logo

Novartis·Phase 1·NCT00002006

AIDS1 trial

Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000711·60 enrolled

Aplastic Anemia1 trial

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Completed·RRoswell Park Cancer Institute·N/A·NCT00053157·10 enrolled

TED1 trial

A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the Gingiva

Completed·IInnoventus Project AB·Phase 1·NCT00689143·10 enrolled

Age1 trial

SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study

Completed·NNiigata University Medical & Dental Hospital·Phase 1·NCT02840708·14 enrolled

Respiratory Failure1 trial

Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)

Completed·UUniversity Hospital, Ghent·Phase 4·NCT04326920·87 enrolled

Donor1 trial

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Completed·WWashington University School of Medicine·Phase 2·NCT01158118·48 enrolled

Diffuse Large B-Cell Lymphoma1 trial

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended·FFavrille·Phase 3·NCT00324831·480 enrolled

Mesothelioma1 trial

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04040231·10 enrolled

PD-11 trial

Sargramostim (GM-CSF) + PD-1

Withdrawn·—·Phase 2·NCT04703426

Safety and Efficacy1 trial

Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT00206661·22 enrolled

Metastatic Colorectal Cancer1 trial

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00088933·60 enrolled

Temozolomide1 trial

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Recruiting·NNationwide Children's Hospital·Phase 1/2·NCT04211675·31 enrolled

Parkinson's Disease1 trial

Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease

Completed·UUniversity of Nebraska·Phase 1·NCT05677633·11 enrolled

Stage III Colon Cancer1 trial

GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262808·50 enrolled

Fallopian Tube Cancer1 trial

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Completed·UUniversity of Washington·Phase 2·NCT00466960·21 enrolled

Transitional Cell Carcinoma1 trial

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Completed·LLudwig Institute for Cancer Research·Phase 1·NCT00070070·6 enrolled

Metastatic Neuroendocrine Tumor1 trial

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03879694·19 enrolled

Malignant Solid Tumors1 trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00436761·20 enrolled

Trial1 trial

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Terminated·VVeeda Oncology·Phase 2·NCT00313482·35 enrolled

Squamous Cell Carcinoma1 trial

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Completed·GGliknik Inc.·Phase 2·NCT02873819·80 enrolled

Intravenous1 trial

Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation

Completed·PPartner Therapeutics, Inc.·Phase 1·NCT05366283·42 enrolled

Cytomegalovirus (CMV)1 trial

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000989·50 enrolled

Osteosarcoma1 trial

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

Completed·CChildren's Oncology Group·Phase 2·NCT00066365·49 enrolled

Gastrointestinal1 trial

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Terminated·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT00012246·7 enrolled

Neutropenia1 trial

A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine

Completed· Novartis logo

Novartis·N/A·NCT00002263

Pancreas Cancer1 trial

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT00669734·18 enrolled

Mucositis1 trial

Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT00004256

Lung Cancer1 trial

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07169617·80 enrolled

Primary Peritoneal Cavity Cancer1 trial

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01536054·7 enrolled

Immunogenicity1 trial

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001090·36 enrolled

Pancreatic Cancer1 trial

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1/2·NCT02620865·2 enrolled

Unspecified2 trials

MIBG With Dinutuximab +/- Vorinostat

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT03332667·45 enrolled

GM-CSF With Post-Transplant Cyclophosphamide

Recruiting·NNorthside Hospital, Inc.·Phase 2·NCT04237623·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 306 trial records for sargramostim. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Leukine drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — sargramostim compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for sargramostim. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Granulocyte-Macrophage Colony-Stimulating Factor Receptor Agonist[3]
Modality: Protein / enzyme[3]
Highest Phase: Approved[1]
Company: Sanofi

Leukine

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Lymphoma18 trials

Melanoma17 trials

Neuroblastoma14 trials

Breast Cancer9 trials

Multiple Myeloma8 trials

Prostate Cancer8 trials

Chronic Lymphocytic Leukemia6 trials

Chronic Myelogenous Leukemia6 trials

Acute Myeloid Leukemia5 trials

Crohn's Disease4 trials

Advanced Cancer4 trials

COVID-193 trials

Non-Small Cell Lung Cancer3 trials

Colorectal Cancer3 trials

Leukemia3 trials

Rhabdomyosarcoma3 trials

Bone Marrow Transplantation3 trials

Effectiveness2 trials

Chemotherapy2 trials

Malignant Glioma2 trials

Acute Lymphoblastic Leukemia2 trials

Stem Cell Transplantation2 trials

Kidney Cancer2 trials

Patients With Solid Tumors2 trials

Glioblastoma Multiforme2 trials

Myelodysplastic Syndrome2 trials

Glioblastoma2 trials

Dendritic Cell2 trials

Moderate to Severe Crohn's Disease2 trials

Metastatic Melanoma2 trials

Hematologic Cancer2 trials

Ovarian Cancer2 trials

Myeloid Neoplasm1 trial

Biological Therapy1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Primary Peritoneal Cancer1 trial

Germ Cell Tumor1 trial

Mantle Cell Lymphoma1 trial

Kaposi's sarcoma1 trial

Adjuvant1 trial

Patients With Advanced Solid Tumors1 trial

Metastatic Cancer1 trial

Brain Tumor1 trial

Invasive Fungal Infection1 trial

Neuroendocrine Carcinoma1 trial

Metastatic Prostate Cancer1 trial

Oligodendroglioma1 trial

Soft Tissue Sarcoma1 trial

Stage III1 trial

Immune1 trial

Interleukin1 trial

HIV infection1 trial

AIDS1 trial

Aplastic Anemia1 trial

TED1 trial

Age1 trial

Respiratory Failure1 trial

Donor1 trial

Diffuse Large B-Cell Lymphoma1 trial

Mesothelioma1 trial

PD-11 trial

Safety and Efficacy1 trial

Metastatic Colorectal Cancer1 trial

Temozolomide1 trial

Parkinson's Disease1 trial

Stage III Colon Cancer1 trial

Fallopian Tube Cancer1 trial

Transitional Cell Carcinoma1 trial

Metastatic Neuroendocrine Tumor1 trial

Malignant Solid Tumors1 trial

Trial1 trial